History

Precision Medicine - Biomarkers & Diagnostics

Acobiom’s history in short cuts

Since its foundation, Acobiom has always been at the forefront of Medical Innovation, in particular in biomarker discovery and diagnostic development, thanks to its expertise and know-how in genomics, transcriptomics, bioinformatics, and biostatistics.

The beginning

Acobiom was founded by Didier Ritter and Dr David Piquemal under the name “Skuldtech” with the support of an academic laboratory from Montpellier University (France): the Transcriptome Study Group led by Pr Jacques Marti and Pr Therese Commes.

Since 1999

Acobiom performs gene expression profiles (called also transcriptomes) based on sequencing technology, and analyzed by a proprietary suite of bioinformatic and biostatistic tools. These gene expression profiles are/were realized as part of partnerships and allowed the discovery of several RNA signatures or acid nucleic (RNA/DNA) biomarkers.
In parallel, the company acquires a unique technical expertise in the development of diagnostics based on RNA/DNA biomarkers and/or PCR (or RT-PCR) technology.
For several years, Acobiom is member of French bioclusters and associations focused on Human Health and Life Science (AFSSI, BioMed Alliance, Cap Digital, Eurobiomed).

2006

Acobiom performed the first world analysis of a transcriptome through « Genome Sequencer System », the first pyrosequencing system. The company used its bioinformatic and biostatistic platform to fulfill this analysis in collaboration with Roche Diagnostics (Switzerland). An Application Note has been issued from this partnership.

2009

Acobiom decided to shift its business model to focus the activity on the discovery of Biomarkers and the development of In-Vitro Diagnostics for Precision Medicine applications.

2011

Acobiom patented its first Blood RNA signature in Precision Medicine. This RNA signature is able to distinguish two “subtypes of chronic myelomonocytic leukaemia patients” and “to predict clinical outcome and help physicians to evaluate criteria for treatments”.

2012

Acobiom patented a Blood RNA signature in pancreatic cancer, fruit of a Precision Medicine program, in which a new treatment and its companion diagnostic were developed.

2014

Acobiom patented a second Blood RNA signature in pancreatic cancer that can predict patient response to gemcitabine (a generic drug) and a 15-month medium survival. Based on this Blood RNA signature, the company developed a new In-Vitro Diagnostic test, called GemciTest®.

2017

Acobiom is part of a collaborative program, called Oncosnipe, which aims to develop and apply artificial intelligence techniques to cancer research. As part of this project, Acobiom develops innovative diagnostics based on data driven medicine and circulating (blood) biomarkers. These diagnostics will be able to predict the patient propensity to develop resistance to cancer drug regimens in pancreatic, lung and breast cancers.

2018

The company is involved in the last step before commercialization of the GemciTest® to comply with the CE mark and FDA requirements.